ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,989.96
      -0.72%
      US Tech 100
      21,189.40
      -0.85%
      Dow Jones
      42,229.54
      -0.67%
      Brent Oil
      75.375
      5.04%
      Bitcoin
      105,128.21
      -1.52%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Bicara Therapeutics Inc (BCAX) Quote

      Bicara Therapeutics Inc

      Bicara Therapeutics Inc (BCAX)

      NASDAQ
      9.72
      -0.28
      ( -2.80% )
      Updated: 15:20:45
      15 min delayed - Upgrade to Realtime

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      9.72
      Bid
      9.69
      Ask
      9.72
      Volume
      285,352
      9.71 Day's Range 10.81
      7.80 52 Week Range 27.95
      Market Cap
      530.092M
      Previous Close
      10.00
      Open
      10.07
      Last Trade
      50
      @
      9.705
      Last Trade Time
      15:22:31
      Financial Volume
      $ 2,863,308
      VWAP
      10.0343
      Average Volume (3m)
      847,662
      Shares Outstanding
      54,536,218
      Dividend Yield
      -
      PE Ratio
      -7.80
      Earnings Per Share (EPS)
      -1.25
      Revenue
      -
      Net Profit
      -68M

      About Bicara Therapeutics Inc

      Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor... Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, or HNSCC, where there remains a significant unmet need. We intend to initiate a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab as a first-line therapy in recurrent/metastatic HNSCC excluding HPV-positive patients with oropharyngeal squamous cell carcinoma late in the fourth quarter of 2024 or early in the first quarter of 2025. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.bicara.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Bicara Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BCAX. The last closing price for Bicara Therapeutics was $10. Over the last year, Bicara Therapeutics shares have traded in a share price range of $ 7.80 to $ 27.95.

      Bicara Therapeutics currently has 54,536,218 shares outstanding. The market capitalization of Bicara Therapeutics is $545.36 million. Bicara Therapeutics has a price to earnings ratio (PE ratio) of -7.80.

      Ask ADVFN Intelligence (AI)

      BCAX Latest News

      More News

      Form 8-K - Current report
      Edgar (US Regulatory)
      June 12 2025
      BCAX (-2.80%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      June 10 2025
      BCAX (-2.80%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      June 06 2025
      BCAX (-2.80%)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      Edgar (US Regulatory)
      May 13 2025
      BCAX (-2.80%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      May 13 2025
      BCAX (-2.80%)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-1.87-16.134598792111.5912.749.6351110411.39942057CS
      4-5.59-36.512083605515.3115.77027.8143398910.70705658CS
      12-4.14-29.870129870113.8616.227.884766211.78188985CS
      26-7.48-43.48837209317.219.757.866948412.80375986CS
      52-16.53-62.971428571426.2527.957.856835914.9360731CS
      156-16.53-62.971428571426.2527.957.856835914.9360731CS
      260-16.53-62.971428571426.2527.957.856835914.9360731CS

      BCAX - Frequently Asked Questions (FAQ)

      What is the current Bicara Therapeutics share price?
      The current share price of Bicara Therapeutics is $ 9.72
      How many Bicara Therapeutics shares are in issue?
      Bicara Therapeutics has 54,536,218 shares in issue
      What is the market cap of Bicara Therapeutics?
      The market capitalisation of Bicara Therapeutics is USD 545.36M
      What is the 1 year trading range for Bicara Therapeutics share price?
      Bicara Therapeutics has traded in the range of $ 7.80 to $ 27.95 during the past year
      What is the PE ratio of Bicara Therapeutics?
      The price to earnings ratio of Bicara Therapeutics is -7.8
      What is the reporting currency for Bicara Therapeutics?
      Bicara Therapeutics reports financial results in USD
      What is the latest annual profit for Bicara Therapeutics?
      The latest annual profit of Bicara Therapeutics is USD -68M
      What is the registered address of Bicara Therapeutics?
      The registered address for Bicara Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE ST, NEW CASTLE, WILMINGTON, DELAWARE, 19801
      What is the Bicara Therapeutics website address?
      The website address for Bicara Therapeutics is www.bicara.com
      Which industry sector does Bicara Therapeutics operate in?
      Bicara Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      CEROCERo Therapeutics Holdings Inc
      $ 20.142
      (193.27%)
      		55.33M
      ACXPAcurx Pharmaceuticals Inc
      $ 0.8261
      (169.00%)
      		316.11M
      RBNERobin Energy Ltd
      $ 12.5764
      (127.83%)
      		42.73M
      EYENEyenovia Inc
      $ 6.35
      (113.80%)
      		19.1M
      VERVVerve Therapeutics Inc
      $ 11.375
      (81.42%)
      		77.84M
      SDSTStardust Power Inc
      $ 0.1909
      (-50.84%)
      		37.04M
      SHOTWSafety Shot Inc
      $ 0.0165
      (-44.63%)
      		10.55k
      RUNSunrun Inc
      $ 5.725
      (-40.61%)
      		105.99M
      SEDGSolarEdge Technologies Inc
      $ 15.7783
      (-34.20%)
      		29.72M
      ADILAdial Pharmaceuticals Inc
      $ 0.2315
      (-28.79%)
      		6.46M
      PCSAProcessa Pharmaceuticals Inc
      $ 0.2666
      (18.44%)
      		564.87M
      GNLNGreenlane Holdings Inc
      $ 0.0107
      (-13.71%)
      		332.05M
      ACXPAcurx Pharmaceuticals Inc
      $ 0.8261
      (169.00%)
      		316.11M
      HCTIHealthcare Triangle Inc
      $ 0.022
      (-16.67%)
      		285.8M
      LCIDLucid Group Inc
      $ 2.145
      (-0.23%)
      		132.26M

      BCAX Discussion

      View Posts
      makinezmoney makinezmoney 3 months ago
      $BCAX: Anyone else seeing a DoubleBottom on the 100day chart

      Now at $13.75.

      Looks like its emerging from that.

      Now at $13.75

      PTs outstanding there from over $30 to $50 on this one............. now only $13.60


      Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and it developing first-in-class biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company's bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, is a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.

      GO $BCAX
      👍️0

      Your Recent History

      NASDAQ
      BCAX
      Bicara Therapeutics
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads